Kamada (KMDA) Stock: Buy, Sell, or Hold?
$8.13
+0.00 (+0.00%)
▲
5d:
+18.34%
30d:
+6.97%
90d:
+7.26%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (51%)
Quality Score
48/100
Position
EXTENDED
30-Day Fair Range
$7.47 – $8.06
Position: EXTENDED
Forward P/E & Valuation
14.0x
FAIR
vs 14.3x historical avg
Wall Street Target
$13.50
+66.1% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$6.77 / $8.35
Trend: Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: KMDA shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When KMDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$13.31
Based on 10.0% avg growth
INTRINSIC VALUE TODAY
$8.26
1.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: KMDA is currently trading at $8.13, which is considered extended relative to its 30-day fair value range of $7.47 to $8.06. The stock's valuation (Forward PE: 14.0) is in line with its historical norms (14.3). Remarkably, the market is currently pricing in an annual earnings decline of 0.7% over the next few years. This pessimistic expectation contrasts with the company's recent 23.1% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, KMDA is in a uptrend. The price is approaching resistance at $8.35. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $13.50 (+66.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KMDA is in a uptrend. The price is approaching resistance at $8.35. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $13.50 (+66.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$7.47 -
$8.06
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
51.0%
Trading Range & Key Levels
30-Day Trading Range
$7.47 -
$8.06
Current vs Trading Range
EXTENDED
Support Level
$6.77
Resistance Level
$8.35
Current Trend
Uptrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (53/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 66.1% below Wall St target ($13.50)
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
14.02
Wall Street Target
$13.50
(+66.1%)
Revenue Growth (YoY)
22.7%
Earnings Growth (YoY)
23.1%
Profit Margin
11.6%
Valuation Discount vs History
-0.7% cheaper
PE vs Historical
14.0 vs 14.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.7%
(market-implied from PE analysis)
1-Year Target
$8.07
(-1%)
2-Year Target
$8.02
(-1%)
3-Year Target
$7.96
(-2%)
3-Yr Target (if PE normalizes)
(PE: 14→14)
$8.12
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 16.0%)
$17.98
(+121%)
Base:
(SPY PE: 14.0, Growth: 16.0%)
$12.69
(+56%)
Bear:
(PE: 11.9, Growth: 16.0%)
$10.79
(+33%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 21.39 | Current EPS (TTM): $0.38
Bull Case
$13.65
(+68%)
Analyst growth 52.6%, PE expands to 23.5
Base Case
$12.41
(+53%)
Market implied 52.6%, PE stable at 21.4
Bear Case
$5.53
(-32%)
Severe decline -20.0%, PE contracts to 18.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.0 to 14.3
Stabilization Target:
$8.29
(+2.0%)
PE Expansion Potential:
+2.0%
Share KMDA Analysis
Share this live KMDA analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (KMDA)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Dec 21, 2025
Daily AI digest
AI Retail Discussion Summary:
One bullish StockTwits message expresses optimism towards $KMDA's long-term potential.
Key Retail Themes:
Bullish sentiment
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 13, 2026 4:57 AM ET
Data refreshes hourly during market hours. Next update: 5:57 AM
Data refreshes hourly during market hours. Next update: 5:57 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KMDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$208 | 23 SELL |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$58 | 41 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 60 BUY |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
15 analysts |
$49 | 36 SELL |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$63 | 51 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive KMDA Research Pages
